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Background: The participation of spinal P2X receptors in neuropathic pain is well recognized. However, the role
of P2Y receptors has been less studied. The purpose of this study was to investigate the contribution of spinal
P2Y6,11 receptors following peripheral nerve damage induced by spinal nerve ligation. In addition, we
determined the expression of P2Y6,11 receptors in the dorsal spinal cord in presence of the selective P2Y6,11
receptors antagonists. Furthermore, we evaluated the participation of spinal microglia and astrocytes in the
pronociceptive role of P2Y6,11 receptors.
Results: Spinal administration of the selective P2Y6 (MRS2578, 10–100 μM) and P2Y11 (NF340, 0.3–30 μM)
receptor antagonists reduced tactile allodynia in spinal nerve ligated rats. Nerve injury increased the expression
of P2Y6,11 receptors at 7, 14 and 21 days after injury. Furthermore, intrathecal administration of MRS2578
(100 μM/day) and NF340 (30 μM/day) for 3 days significantly reduced spinal nerve injury-induced increase in
P2Y6,11 receptors expression, respectively. Spinal treatment (on day 14 after injury) with minocycline (100 μg/day) or
fluorocitrate (1 nmol/day) for 7 days reduced tactile allodynia and spinal nerve injury-induced up-regulation in Iba-1
and GFAP, respectively. In addition, minocycline reduced nerve injury-induced up-regulation in P2Y6,11 receptors
whereas that fluorocitrate diminished P2Y11, but not P2Y6, receptors up-regulation. Intrathecal treatment (on day 21
after injury) with the selective P2Y6 (PSB0474, 3–30 μM) and P2Y11 (NF546, 1–10 μM) receptor agonists produced
remarkable tactile allodynia in nerve ligated rats previously treated with minocycline or fluorocitrate for 7 days.
Conclusions: Our data suggest that spinal P2Y6 is present in spinal microglia while P2Y11 receptors are present in both
spinal microglia and astrocytes, and both receptors are up-regulated in rats subjected to spinal nerve injury. In addition,
our data suggest that the spinal P2Y6 and P2Y11 receptors participate in the maintenance of neuropathic pain.
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ATP (adenosine triphosphate) is released from primary af-
ferents following peripheral tissue/nerve damage producing
pain [1,2]. The pronociceptive role of ATP in nociception is
well characterized [3-8]. This effect has been associated
with the activation of the P2X family receptors expressed in
dorsal root ganglion [9-12], satellite glial cells [13,14], spinal* Correspondence: vinicio_granadossoto@hotmail.com
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article, unless otherwise stated.dorsal horn [15-17] and microglia/astrocytes [16,18,19].
Following nerve damage, spinal microglia and astrocytes
proliferate and up-regulate specific protein markers like
ionized calcium-binding adapter molecule-1 (Iba-1) and
glial fibrillary acidic protein (GFAP), respectively [20,21]. It
is thought that these changes are involved in neuropathic
pain as activated microglia and astrocytes have the ability
to modify and modulate neuronal firing and to release pro-
and anti-inflammatory molecules. Importantly, spinal
microglia is activated by ATP through P2X4 and P2X7 re-
ceptors leading to release of pro-inflammatory cytokines
(interleukin-1β [IL-1β]), tumor necrosis factor α [TNFα],d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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and neurotrophic factors (brain derived neurotrophic
factor [BDNF]), among others, to produce central
sensitization [22-24].
In comparison to P2X receptors, the contribution of
P2Y receptors to neuropathic pain has been less studied.
At the moment, there is limited evidence to suggest that
P2Y receptors play a role in neuropathic pain. However,
data have shown that P2Y1 receptors mRNA is up-
regulated in rat dorsal root ganglion neurons after per-
ipheral axotomy of the sciatic nerve [25]. Likewise,
P2Y1 and P2Y2 receptors mRNAs are up-regulated in
mouse L2/L3 dorsal root ganglion neurons after nerve
transection [26]. P2Y receptors might also be involved
in spinal microglia activation during neuropathic pain
conditions. In this sense, P2Y12 receptors are up-regulated
in spinal microglia after peripheral nerve injury [27]. More-
over, P2Y6, P2Y13 and P2Y14 mRNAs are up-regulated in
microglia in the ipsilateral spinal cord following nerve
injury [28]. Furthermore, recent evidence suggests that
some P2Y receptors are expressed in satellite glial cells
and astrocytes and they contribute to neuropathic pain
following nerve damage [29].
Due to the limited information about the participation
of P2Y receptors in neuropathic pain, we decided to
study the role of spinal P2Y6 and P2Y11 receptors in the
maintenance of neuropathic pain in the rat by pharma-
cological and molecular methods. Our data suggest that
spinal P2Y6 is present in spinal microglia while P2Y11 re-
ceptors are present in both spinal microglia and astrocytes,
and both receptors are up-regulated in rats subjected to
spinal nerve injury. In addition, our data suggest that the
spinal P2Y6 and P2Y11 receptors participate in the mainten-
ance of neuropathic pain.
Results
Antiallodynic effects of selective P2Y6 (MRS2578) and
P2Y11 (NF340) receptor antagonists in rats
Spinal nerve injury produced tactile allodynia in the
ipsilateral hind paw, which was evident by a significant
decrease in the 50% paw withdrawal threshold response as
compared to the naive group (Figure 1A/C). As expected,
sham surgery did not change the 50% withdrawal threshold
response on the ipsilateral side as previously reported by
our group [30]. Furthermore, intrathecal administration of
vehicle did not affect tactile allodynia induced by spinal
nerve ligation (Figure 1A/C). In marked contrast, the spinal
administration of the selective P2Y6 (MRS2578, Figure 1A)
and P2Y11 (NF340, Figure 1C) receptor antagonists pro-
duced an antiallodynic effect in the spinal nerve injured
rats. The maximal antiallodynic effect in both cases was
reached in about 1 h and then decayed gradually in
about 6 h. However, MRS2578 had a greater peak effect
than NF340, although the effect of the later decayedmore slowly. MRS2578 (10–100 μM, Figure 1B) and
NF340 (0.3–30 μM, Figure 1D) reversed significantly
(p < 0.05) and dose-dependently tactile allodynia in the
spinal nerve injured rats.
Expression of P2Y6 and P2Y11 receptors in spinal nerve
injured rats: effects of MRS2578 and NF340
Western blot analysis showed bands of about 36 and
75 kDa for P2Y6 (Figure 2A) and P2Y11 (Figure 2B) re-
ceptors at the ipsilateral dorsal spinal cord, respectively.
Spinal nerve ligation produced a significant (p < 0.05)
increase in the expression of P2Y6 and P2Y11 receptors
at 7 and 14 days (Figure 2A/B), as well as 21 days after
nerve injury (Additional file 1: Figure S1). No significant
(p > 0.05) increase of P2Y6 (Additional file 2: Figure S2A)
and P2Y11 (Additional file 2: Figure S2B) receptors ex-
pression was observed in the contralateral dorsal
spinal cord. There were no immunoreactive bands for
both receptors when the primary antibodies were pre-
adsorbed with the corresponding antigenic peptides
(Figure 2C).
Repeated intrathecal administration (starting on day
12 after nerve injury) of the selective P2Y6 (MRS2578,
100 μM/12 h for 3 days) and P2Y11 (NF340, 30 μM/12 h
for 3 days) receptor antagonists, but not vehicle, signifi-
cantly (p < 0.05) reversed spinal nerve ligation-induced
increase in P2Y6 (Figure 3A) and P2Y11 (Figure 3B) re-
ceptors expression in the dorsal spinal cord on day 14
after nerve injury.
Effect of minocycline or fluorocitrate on tactile allodynia,
glial markers, and P2Y6,11 receptors expression
Spinal nerve injury produced tactile allodynia as well
as a significant (p < 0.05) increase in the expression of
microglia and astrocytes markers Iba-1 (Figure 4A) and
GFAP (Figure 4C), respectively, 21 days later. This increase
was only evident in the ipsilateral, but not contralateral,
section of the dorsal spinal cord (Figure 4B/D).
Once established tactile allodynia (14 days after nerve
injury), repeated intrathecal treatment with minocycline
(100 μg/day for 7 days, Figure 4E) or fluorocitrate
(1 nmol/day for 7 days, Figure 4F), but not vehicle, re-
duced tactile allodynia in the spinal nerve ligated rats
and diminished the increase in microglia and astro-
cytes markers Iba-1 (Figure 4A) and GFAP (Figure 4C)
in the ipsilateral, but not contralateral, section of the
dorsal spinal cord (Figure 4B/D). Moreover, repeated
intrathecal administration of minocycline significantly
(p < 0.05) reduced spinal nerve injury-induced increase in
P2Y6 (Figure 5A) and P2Y11 (Figure 5B) expression in
rats. In contrast, repeated intrathecal injection of fluor-
ocitrate only diminished the increase of P2Y11 (Figure 5D),
but not P2Y6 (Figure 5C), receptors expression in the
same schedule.
Figure 1 Intrathecal injection of the selective P2Y6,11 receptor antagonists reverses tactile allodynia. Time course of the antiallodynic
effects of the selective P2Y6 (MRS2578, panel A) and P2Y11 (NF340, panel C) receptor antagonists in rats submitted to spinal nerve injury. Data are
expressed as mean ± S.E.M. for 6 animals. Withdrawal threshold was assessed 14 days after spinal nerve injury. Dose–response curves of the
antiallodynic effect of MRS2578 (10–100 μM, panel B) and NF340 (0.3–30 μM, panel D). Data are expressed as the 50% threshold withdrawal
against time curve (AUC). * Significantly different from the vehicle (Veh) group (p < 0.05), as determined by analysis of variance followed by the
Student-Newman-Keuls test. N: Naive.
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receptor agonists in spinal nerve injured rats pre-treated
with minocycline or fluorocitrate
Once established tactile allodynia (14 days), repeated
intrathecal treatment with minocycline (100 μg/day for
7 days, Additional file 3: Figure S3A/B) or fluorocitrate
(1 nmol/day for 7 days, Additional file 3: Figures S3C/D)
reversed spinal nerve injury-induced tactile allodynia.
On this condition, a bolus intrathecal injection with the
selective P2Y6 (PSB0474, 3–30 μM; Additional file 3:
Figure S3A/C) and P2Y11 (NF546, 1–10 μM; Additional
file 3: Figure S3B/D) receptor agonists produced a remark-
able and long-lasting tactile allodynia in the rats pretreated
with minocycline or fluorocitrate. In contrast, intrathecaladministration of vehicles did not modify the withdrawal
threshold (Additional file 3: Figure S3A-D).
Discussion
This study demonstrates that intrathecal administration
of MRS2578 and NF340 partially reverses spinal nerve
injury-induced tactile allodynia. Since these drugs are
selective P2Y6 [31] and P2Y11 [32] receptor antagonists,
respectively, our data suggest that both spinal receptors
participate in the maintenance of neuropathic pain induced
by spinal nerve injury. Our results agree with a previous re-
port showing that intrathecal administration of MRS2578
suppresses spared nerve injury-induced mechanical allody-
nia [28], suggesting that spinal P2Y6 receptors participate in
Figure 3 P2Y6,11 receptor antagonists prevent enhanced expression of P2Y6,11 receptors. Effect of the repeated intrathecal administration
of MRS2578 (panel A) and NF340 (panel B) in spinal nerve injury-induced increase in P2Y6 and P2Y11 expression in the ipsilateral dorsal spinal
cord. Data were normalized against β-actin and are expressed as the mean ± S.E.M. of 3 independent rats. * Significantly (p < 0.05) different from
the naïve (N) group and # significantly (p < 0.05) different from the spinal nerve ligated (SNL) group, as determined by one-way analysis of
variance followed by the Student-Newman-Keuls test.
Figure 2 Spinal nerve injury enhances the expression of P2Y6,11 receptors. Western blot analysis of the P2Y6 (panel A) and P2Y11 (panel B)
receptors expression in the ipsilateral dorsal spinal cord obtained from naïve and spinal nerve injured (SNL) rats. The primary antibody for P2Y6
and P2Y11 were pre-adsorbed with the corresponding antigenic peptide (+P, panel C). Data were normalized against β-actin and are expressed as
the mean ± S.E.M. of 3 independent rats. *Significantly (p < 0.05) different from the naïve (N) group, as determined by one-way analysis of variance
followed by the Student-Newman-Keuls test.
Barragán-Iglesias et al. Molecular Pain 2014, 10:29 Page 4 of 11
http://www.molecularpain.com/content/10/1/29
Figure 4 Spinal nerve injury increases the expression of Iba-1 and GFAP: Blockade by minocycline or fluorocitrate. Effect of the repeated
intrathecal administration of minocycline (Mino, panel A and B) or fluorocitrate (Fluo, panel C and D) in spinal nerve injury-induced increased
expression of Iba-1 and GFAP in the ipsilateral (IL) and contralateral (CL) dorsal spinal cord. Minocycline (panel E) and fluorocitrate (panel F) also
reduced tactile allodynia in spinal nerve ligated rats. Data were normalized against β-actin and are expressed as the mean ± S.E.M. of 3 independent
rats. * Significantly (p < 0.05) different from the sham (S) or naïve (N) groups and # significantly (p < 0.05) different from the spinal nerve ligated (SNL)
group, as determined by one-way analysis of variance followed by the Student-Newman-Keuls test.
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Figure 5 Spinal nerve injury increases the expression of P2Y6 and P2Y11: Blockade by minocycline or fluorocitrate. Effect of the repeated
intrathecal administration of minocycline (Mino, panel A and B) or fluorocitrate (Fluo, panel C and D) in spinal nerve injury-induced increased
expression of P2Y6 and P2Y11 receptors in the ipsilateral dorsal spinal cord. Data were normalized against β-actin and are expressed as the
mean ± S.E.M. of 3 independent rats. * Significantly (p < 0.05) different from the naïve (N) group and # significantly (p < 0.05) different from the
spinal nerve ligated (SNL) group, as determined by one-way analysis of variance followed by the Student-Newman-Keuls test.
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disagree with other study demonstrating that P2Y6 re-
ceptors play an antinociceptive role as intrathecal uridine
diphosphate (UDP) administration (endogenous agonist)
shows antiallodynic effects after partial sciatic nerve ligation
[33]. This discrepancy could be explained on the basis
of the used P2Y6 receptor agonist selectivity as UDPalso activates the P2Y14 receptor with higher affinity than
for P2Y6 receptors [34]. In our study we demonstrated that
intrathecal administration of the selective P2Y6 (PSB0474)
and P2Y11 (NF546) receptor agonists produces long-lasting
tactile allodynia which argues against the antinocicep-
tive effect of spinal P2Y6 receptors. Regarding NF340,
this seems to be the first report demonstrating the
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that spinal P2Y11 receptors play an important role in
the maintenance of neuropathic pain. The contribu-
tion of P2Y6 receptors seems to be different from that
of P2Y11 receptors as the P2Y6 receptor antagonist
produced a peak in the antiallodynic effect in about
1–2 h and then decayed rapidly. In contrast, the P2Y11
receptor antagonist produced a modest but sustained
antiallodynic effect. This discrepancy could be due to
differences in the pharmacokinetics or pharmacodynamics
of the tested drugs. Taken together, our data suggest the
participation of spinal P2Y6,11 receptors in the mainten-
ance of neuropathic pain.
In support to our pharmacological study, we demon-
strated by western blot that P2Y6,11 receptors are expressed
in the dorsal spinal cord of naïve rats. Previous studies
indicate that P2Y6 receptor mRNA is found in rat micro-
glia [35]. On the contrary, P2Y11 receptors have only been
described in humans. Currently there are no reports of a
cloned P2Y11 receptor in rats. However, this receptor has
been recently reported in epithelial cells [36], primary glial
cells [37], lacrimal glands [38], neutrophils [39], and brain
[38] of rats. Thus, our data suggest that the P2Y6 receptor
is expressed and completely functional in the spinal
cord. In addition, our results suggest the presence of a
P2Y11–like receptor in the rat spinal cord. Besides their
presence in naïve animals, P2Y6,11 receptors expression
in the ipsilateral dorsal spinal cord was up-regulated at
7 and 14 days after spinal nerve ligation. These results
partially agree with a previous study showing that P2Y6
receptor mRNA is up-regulated in the ipsilateral spinal
cord at 3 days following peripheral nerve injury [28].
This time difference may be due to the neuropathic pain
model or the method used to quantify the expression of
the P2Y6 receptor (PCR versus WB). In the case of P2Y11
receptors, this is the first report about their increased ex-
pression. To further reinforce the participation of spinal
P2Y6,11 receptors in the maintenance of neuropathic pain
in rats, we demonstrated that intrathecal administration
of the P2Y6,11 receptor antagonists reverses spinal nerve
injury-induced tactile allodynia and P2Y6,11 receptors
up-regulation. Admittedly, the mechanisms for the sup-
pressive effects of P2Y6,11 receptor antagonists on the
up-regulation of these receptors in the dorsal spinal
cord after nerve injury are unclear. However, it is likely
that blockade of both receptors may lead to a fall in cen-
tral sensitization that then could promote the reduction
in P2Y6,11 receptors expression. Clearly, further experi-
ments which fall beyond the scope of our study will be
required to confirm our suggestion.
It is accepted that spinal microglia and astrocytes release
several pro-inflammatory mediators in the dorsal horn
following nerve damage [22,24]. We confirmed the
participation of microglia and astrocytes by showingthat the ipsilateral, but not contralateral, spinal Iba-1 and
GFAP are up-regulated in spinal nerve injured rats and
this up-regulation is prevented by repeated administration
of intrathecal minocycline or fluorocitrate, respectively.
More important, spinal nerve injury increased expression
of P2Y6,11 receptors in the dorsal spinal cord whereas that
treatment with minocycline reduced spinal nerve damage-
induced P2Y6,11 receptors enhanced expression. Thus, our
data seem to point out that spinal P2Y6,11 receptors are
present in activated microglia and they participate in the
maintenance of neuropathic pain in the rat. In support of
this, Kobayashi and coworkers reported the enhanced
presence of P2Y6,13,14 receptors mRNA in spinal microglia
following peripheral nerve injury [28]. Furthermore, intra-
thecal administration of the microglial p-38 MAPK inhibi-
tor SB203580 suppressed spinal nerve injury-induced
increase of P2Y6 mRNA suggesting that activated microglia
leads to an enhanced expression of P2Y6 receptors and
neuropathic pain [28].
We showed that fluorocitrate reduces spinal P2Y11,
but not P2Y6, receptors up-regulation suggesting that
activated astrocytes are over-expressing P2Y11 recep-
tors and this phenomenon contributes to maintenance
of neuropathic pain. In support of this, P2Y11 receptors
have been found in astrocytes [37]. However, the fact
that intrathecal administration of selective agonists of
the P2Y6,11 receptors produced tactile allodynia once
microglia and astrocytes have been previously blocked
suggests that spinal P2Y6,11 receptors may participate
promoting neuropathic pain at least partially in a microglia-
or astrocytes-independent way. Supporting this, P2Y6, but
not P2Y11, receptors mRNA have been found in dorsal
root ganglion [26,40,41]. Taken together, data suggest
that P2Y6,11 receptors are present in microglia while
P2Y11 receptors are present only in astrocytes.
We found that repeated injections (for 7 days) of
minocycline or fluorocitrate produced an antiallodynic
effect in neuropathic rats. These data suggest that
microglia and astrocytes play an important role in the
maintenance phase of neuropathic pain. These data agree
with previous observations showing that repeated treat-
ment with minocycline reverses thermal hyperalgesia and
mechanical allodynia [42-46]. In contrast, others have
reported that minocycline prevents but do not reverses
established neuropathic pain [47-49]. Differences could
be due to the different models of neuropathic pain used.
Regarding fluorocitrate, this drug reverses both ipsilateral
and mirror-image spinal nerve injury-induced allodynia
[49,50] which agree with our observations.
Conclusion
Our data suggest that spinal P2Y6,11 receptors are present
in spinal microglia while P2Y11 receptors are present
only in astrocytes. Both receptors are up-regulated in
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that the spinal P2Y6 and P2Y11 receptors participate in
the maintenance of neuropathic pain.
Methods
Animals
Since previous experiments in our conditions found no
differences between male and female rats [30], all experi-
ments were performed on female Wistar rats (140–180 g).
Animals were obtained from our own breeding facilities
and had free access to food and drinking water. All experi-
ments followed the Guidelines on Ethical Standards for
Investigation of Experimental Pain in Animals [51] and the
Mexican regulation (NOM-062-ZOO-1999). In addition,
these experiments were approved by our local Ethics Com-
mittee (Protocol 455-09, Cinvestav, México City, México).
Induction of spinal nerve ligation and measurement of
tactile allodynia
Rats were prepared according to the method of [52]. Briefly,
animals were anesthetized with a mixture of ketamine
(50 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.). After surgical
preparation and exposure of the dorsal vertebral column,
the left L5 and L6 spinal nerves were exposed and tightly li-
gated with 6-0 silk suture distal to the dorsal root ganglion.
For sham-operated rats, the nerves were exposed but not
ligated. Tactile allodynia was determined according to a
previously reported method [53]. Fourteen days after sur-
gery, rats were transferred to clear plastic, wire mesh-
bottomed cages and allowed to acclimatize for 30–40 min.
Von Frey filaments (Stoelting, Wood Dale, IL, USA)
were used to determine the 50% paw withdrawal thresh-
old using the up-down method [54]. Allodynia was con-
sidered to be present when paw withdrawal thresholds
were less than 4 g.
Spinal catheterization
Chronic catheterization of the spinal subarachnoid space
was performed as described [55]. Seven or nine days
after spinal nerve injury, rats were again anesthetized
with a ketamine (45 mg/kg, i.p.)/xylazine (12 mg/kg, i.p.)
mixture, placed in a stereotaxic head holder, and the
atlantooccipital membrane exposed. The membrane was
pierced, and a polyethylene catheter (PE-10, 7.5 cm length)
was inserted intrathecally and advanced caudally to the
level of the thoracolumbar junction. Rats were allowed
to recover from surgery for 5 days in individualized
cages before drugs administration and testing. For
spinal drug administration, rats received an intrathecal
(i.t.) injection of vehicle (10 μl) or increasing concen-
trations of the P2Y6,11 receptor antagonists (μM/10 μl).
The antiallodynic effect was evaluated for the following




(1,3-xylene-alpha,alpha'-diphosphonic acid tetrasodium salt
(NF546), N,N"-1,4-butanediylbis[N'-(3-isothiocyanatophenyl)
thiourea (MRS2578) and 4,4'-(carbonylbis(imino-3,1-
(4-methyl-phenylene)carbonylimino))bis(naphthalene-2,6-
disulfonic acid) tetrasodium salt (NF340) were purchased
from Tocris Bioscience (Ellisville, MO). The purinergic
drugs mentioned above were selected based on relevant
receptor selectivity and efficacy. These included: (i) select-
ive P2Y6 and P2Y11 receptors agonists PSB0474 [56] and
NF546 [32], respectively, and (ii) selective P2Y6 and P2Y11
receptors antagonists MRS2578 [31] and NF340 [32], re-
spectively. The doses used for P2Y6,11 receptor antagonists
were chosen based in previous studies [28,32,57].
Minocycline hydrochloride (microglial inhibitor) and
DL-fluorocitric acid barium salt (fluorocitrate, astro-
cytic inhibitor) were purchased from Sigma-Aldrich
(St. Louis, MO). PSB0474, NF340 and NF546 were dissolved
in 0.9% saline solution. MRS2578 and minocycline was
dissolved in 20% DMSO. Fluorocitrate was dissolved
initially in 2 M HCl (0.1 μmol/μL) and then diluted in
0.01 M PBS to attain a final concentration of 0.1 nmol/μL
(pH 6.0). The vehicle control for fluorocitrate was 0.1%
2 M HCl in 0.01 M PBS (pH 6.0) [50].
Western blot analysis
Western blot analysis was used to detect changes in the
expression of P2Y6,11 receptors as well as Iba-1 and GFAP
protein levels in the lumbar ipsilateral and contralateral
dorsal spinal cord. For this purpose, naïve and ligated rats
were sacrificed by decapitation. The lumbar region of the
spinal cord (L4–L6) was sectioned to get the ipsilateral
section of the dorsal spinal cord. Immediately, tissues were
stored at −70°C. Tissues from individual animals were
homogenized in ice-cold lysis buffer (in mM: 150 NaCl, 50
Tris–HCl, 5 EDTA), pH 7.4 for 30 min at 4°C. The protease
inhibitors PMSF (1 mM), aprotinin (10 μg/mL), leupeptin
(10 μg/mL), pepstatin A (10 μg/mL) and the surfactant
0.1% Triton X-100 (Sigma-Aldrich, St. Louis, MO) were
added to the lysis buffer immediately prior to use. The
homogenate was then centrifuged (Eppendorf, Hamburg) at
14,000 rpm for 10 min to remove cellular debris. The re-
sultant supernatant was used to measure protein concentra-
tion by the Bradford’s method (Bio-Rad, Hercules, CA).
Fifty (for Iba-1 and GFAP) or one hundred (for P2Y6 and
P2Y11 receptors) μg of proteins were resolved by denaturing
by 10% or 12% (for Iba-1) SDS–polyacrylamide gel electro-
phoresis and transferred to PVDF membranes. Membranes
were incubated in 5% non-fat milk in phosphate-buffered
saline (PBS) at pH 7.4 (in mM: 137 NaCl, 2.7 KCl, 10
Na2HPO4 and 2 KH2PO4) with 0.1% Tween 20 for 1 h to
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cubated overnight at 4°C in 5% non-fat dry milk/PBS
containing rabbit anti-P2Y6 (BML-SA586-0050, 1:100,
Enzo Life Sciences, Farmingdale, NY), rabbit anti-P2Y11
(AB9590, 1:500, Millipore, Billerica, MA), mouse anti-Iba-1
(MABN92, 1:500, Millipore, Bellerica, MA) or rabbit
anti-GFAP (AB5804, 1:1000, Millipore, Bellerica, MA)
antibodies. Membranes were incubated for 1 h at room
temperature in 1% non-fat milk/PBS containing the
horseradish peroxidase-conjugated secondary antibody
(Donkey anti-rabbit, 711-035-152, 1:6000 or Donkey
anti-mouse, 715-036-150, 1:5000; Both of Jackson
immnunoresearch, West Grove, PA). Protein signal de-
tection was achieved with the ECL chemiluminescence
system (ECL plus, Amersham, UK). The next day, blots
were stripped and incubated with a monoclonal antibody
directed against β-actin (1:10000, MAB1501R, Millipore,
Billerica, MA) which was used as an internal control to
normalize P2Y6 and P2Y11 receptors and Iba-1 and GFAP
protein expression levels. Scanning of the immunoblots
was performed and the bands were quantified by densitom-
etry using an image analysis program (LabWorks; UVP
Inc., Upland, CA). In addition, control peptides for P2Y6,11
receptors were tested to determinate the bands specificity.
Experimental design
In order to determine the role of spinal P2Y6,11 recep-
tors in the neuropathic pain induced by spinal nerve
ligation, neuropathic animals (14 days later) were intra-
thecally administered with vehicle or increasing doses of
the selective P2Y6 (MRS2578, 10–100 μM) and P2Y11
(NF340, 0.3–30 μM) receptor antagonists.
As selective P2Y6,11 receptor antagonists produced
antiallodynic effects, we next determined the expression
of these receptors at the ipsilateral and contralateral
dorsal spinal cord at 1, 3, 7 and 14 days after injury. Fur-
thermore, to confirm the participation of the spinal
P2Y6,11 receptors in the processing of neuropathic pain
in rats, the expression of these receptors in absence and
presence of the selective P2Y6,11 receptor antagonists was
determined. For this, we administered the P2Y6 (100 μM)
and P2Y11 (30 μM) receptor antagonists every 12 h for
3 days starting on day 12 after ligation. Rats were sacrificed
on day 14 after nerve ligation.
In order to investigate the role of microglia and astrocytes
in spinal nerve injury-induced tactile allodynia, rats were li-
gated and intrathecally canulated. On day 14, these animals
received a daily intrathecal injection of vehicle, minocycline
(100 μg/day) or fluorocitrate (1 nmol/day) for seven days.
Tactile allodynia was determined 24 h after the first admin-
istration and then every other day until day 21. Rats were
sacrificed on day 21 to determine the protein expression of
Iba-1 and GFAP in the ipsilateral and contralateral dorsal
spinal cord.As our data showed the participation of microglia and
astrocytes in neuropathic pain induced by spinal nerve
ligation, we next investigated the role of the spinal puri-
nergic P2Y6,11 receptors in the same conditions. To fur-
ther confirm the participation of glial cells and spinal
P2Y6,11 receptors, we next evaluated the effect of selective
P2Y6 (PSB0474, 3–30 μM) and P2Y11 (NF546, 1–10 μM)
receptor agonists in rats previously treated with minocy-
cline or fluorocitrate for 7 days.
Data analysis and statistics
All behavioral results are given as the mean ± S.E.M. for
six animals per group. Curves were constructed by plotting
the threshold for paw withdrawal as a function of time. An
increase of 50% withdrawal threshold was considered as
antiallodynia.
For protein expression, all results are given as the mean
relative intensity ± S.E.M. for 3 animals per group.
One- or two-way analysis of variance, followed by the
Student-Newman-Keuls was used to compare differences
between groups. Differences were considered to reach
statistical significance when p < 0.05.
Additional files
Additional file 1: Figure S1. Spinal nerve injury enhances the
expression of P2Y6,11 receptors at 21 days after injury. Western blot
analysis of the P2Y6 and P2Y11 receptors expression in the ipsilateral
dorsal spinal cord obtained 21 days after nerve injury from naïve and
spinal nerve injured rats. Data were normalized against β-actin and are
expressed as the mean ± S.E.M. of 3 independent rats. *Significantly
(p < 0.05) different from the naïve group, as determined by one-way
analysis of variance followed by the Student-Newman-Keuls test.
Additional file 2: Figure S2. Full blots of the P2Y6 and P2Y11 protein
expression in the contralateral dorsal spinal cord. Western blot analysis of
the P2Y6 (panel A) and P2Y11 (panel B) receptors expression in the
contralateral dorsal spinal cord obtained from naïve (N) and spinal nerve
injured rats (SNL). Data were normalized against β-actin and are
expressed as the mean ± S.E.M. of 3 independent rats.
Additional file 3: Figure S3. Repeated intrathecal minocycline or
fluorocitrate reduces tactile allodynia: Effects of P2Y6,11 receptor agonists.
Effect of the intrathecal treatment with minocycline (green symbols) or
fluorocitrate (purple symbols) in spinal nerve injured rats (panels A-D).
Time course of the allodynic effect of PSB0474 and NF546 in rats
previously treated with repeated intrathecal minocycline (panels A and B)
or fluorocitrate (panels C and D), respectively. Data are expressed as
mean ± S.E.M. for 6 animals. *Significantly (p < 0.05) different from the
vehicle (Veh) group, as determined by two-way analysis of variance
followed by the Student-Newman-Keuls test.
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derived neurotrophic factor; CCL-2: Chemokine ligand 2; CCL-3: Chemokine
ligand 3; GFAP: Glial fibrillary acidic protein; Iba-1: Ionized calcium-binding
adapter molecule-1; IL-1β: Interleukin-1β; IL-6: Interleukin-6; MRS2578: N,
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tetrasodium salt; NF546: 4,4'-(Carbonylbis(imino-3,1-phenylene-carbonylimino-3,
1-(4-methyl phenylene)carbonylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic
acid tetrasodium salt; PBS: Phosphate-buffered saline; PSB0474: 3-(2-Oxo-2-
phenylethyl)-uridine-5'-diphosphate disodium salt; TNFα: Tumor necrosis
factor α; UDP: Uridine diphosphate.
Barragán-Iglesias et al. Molecular Pain 2014, 10:29 Page 10 of 11
http://www.molecularpain.com/content/10/1/29Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
PB-I carried out the molecular and pharmacological studies, performed the
statistical analysis and drafted the manuscript. JBP-F carried out the molecular
studies. CC-D participated in the pharmacological studies. MB-H participated in
the molecular and pharmacological studies. HIR-G participated in the design
and coordination of the study and helped to draft the manuscript. JM
participated in the design, coordination and helped to draft to manuscript.
VG-S conceived the idea, participated in the design and coordination of the
study. He also helped to interpret the data and to draft the final manuscript.
All authors read and approved the final manuscript.
Authors’ information
PB-I, JBP-F, CC-D and MB-H are graduate students at the Department of
Pharmacobiology in Cinvestav, South Campus. Mexico City, Mexico. HIR-G is
a full professor at the Sección de Estudios de Posgrado e Investigación at
the Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico
City, Mexico. JM is a full professor at the Department of Pharmacobiology
in Cinvestav, South Campus. Mexico City, Mexico. VG-S is a full professor
at the Department of Pharmacobiology in Cinvestav, South Campus.
Mexico City, Mexico.
Acknowledgements
The authors greatly appreciate the bibliographic assistance of B.Sc. Pilar
Quinteros-Carrillo. Graduate students Paulino Barragán-Iglesias, Jorge B.
Pineda-Farias, Claudia Cervantes-Durán and Mariana Bravo-Hernández are Conacyt
fellows. Partially supported by Conacyt (grant CB-2012/179294 to VG-S).
Author details
1Neurobiology of Pain Laboratory, Departamento de Farmacobiología,
Centro de Investigación y de Estudios Avanzados (Cinvestav), Sede Sur,
Calzada de los Tenorios 235, Colonia Granjas Coapa, 14330 México, D.F.,
México. 2Sección de Estudios de Posgrado e Investigación, Escuela Superior
de Medicina, Instituto Politécnico Nacional, México D.F., México.
Received: 3 March 2014 Accepted: 10 May 2014
Published: 20 May 2014
References
1. Chizh BA, Illes P: P2X receptors and nociception. Pharmacol Rev 2001,
53:553–568.
2. Wirkner K, Sperlagh B, Illes P: P2X3 receptor involvement in pain states.
Mol Neurobiol 2007, 36:165–183.
3. Bleehen T, Keele CA: Observations on the algogenic actions of adenosine
compounds on the human blister base preparation. Pain 1977, 3:367–377.
4. Hamilton SG, Warburton J, Bhattacharjee A, Ward J, McMahon SB: ATP in
human skin elicits a dose-related pain response which is potentiated
under conditions of hyperalgesia. Brain 2000, 123(Pt 6):1238–1246.
5. Hilliges M, Weidner C, Schmelz M, Schmidt R, Orstavik K, Torebjork E,
Handwerker H: ATP responses in human C nociceptors. Pain 2002,
98:59–68.
6. Jarvis MF, Wismer CT, Schweitzer E, Yu H, van Biesen T, Lynch KJ, Burgard
EC, Kowaluk EA: Modulation of BzATP and formalin induced nociception:
attenuation by the P2X receptor antagonist, TNP-ATP and enhancement
by the P2X3 allosteric modulator, cibacron blue. Br J Pharmacol 2001,
132:259–269.
7. Sawynok J: Adenosine and ATP receptors. Handb Exp Pharmacol 2007,
177:309–328.
8. Nakagawa T, Wakamatsu K, Zhang N, Maeda S, Minami M, Satoh M, Kaneko
S: Intrathecal administration of ATP produces long-lasting allodynia in
rats: differential mechanisms in the phase of the induction and
maintenance. Neuroscience 2007, 147:445–455.
9. Kage K, Niforatos W, Zhu CZ, Lynch KJ, Honore P, Jarvis MF: Alteration of
dorsal root ganglion P2X3 receptor expression and function following
spinal nerve ligation in the rat. Exp Brain Res 2002, 147:511–519.
10. Ueno S, Yamada H, Moriyama T, Honda K, Takano Y, Kamiya HO, Katsuragi T:
Measurement of dorsal root ganglion P2X mRNA by SYBR Green
fluorescence. Brain Res Brain Res Protoc 2002, 10:95–101.11. Sharp CJ, Reeve AJ, Collins SD, Martindale JC, Summerfield SG, Sargent BS,
Bate ST, Chessell IP: Investigation into the role of P2X3/P2X2/3 receptors in
neuropathic pain following chronic constriction injury in the rat: an
electrophysiological study. Br J Pharmacol 2006, 148:845–852.
12. Xiang Z, Xiong Y, Yan N, Li X, Mao Y, Ni X, He C, LaMotte RH, Burnstock G,
Sun J: Functional up-regulation of P2X3 receptors in the chronically
compressed dorsal root ganglion. Pain 2008, 140:23–34.
13. Zhang X, Chen Y, Wang C, Huang LY: Neuronal somatic ATP release
triggers neuron-satellite glial cell communication in dorsal root ganglia.
Proc Natl Acad Sci U S A 2007, 104:9864–9869.
14. Gosselin RD, Suter MR, Ji RR, Decosterd I: Glial cells and chronic pain.
Neuroscientist 2010, 16:519–531.
15. Kim C, Chung JM, Chung K: Changes in the gene expression of six
subtypes of P2X receptors in rat dorsal root ganglion after spinal nerve
ligation. Neurosci Lett 2003, 337:81–84.
16. Inoue K: The function of microglia through purinergic receptors:
neuropathic pain and cytokine release. Pharmacol Ther 2006, 109:210–226.
17. North RA: Molecular physiology of P2X receptors. Physiol Rev 2002,
82:1013–1067.
18. Donnelly-Roberts D, McGaraughty S, Shieh CC, Honore P, Jarvis MF: Painful
purinergic receptors. J Pharmacol Exp Therapeut 2008, 324:409–415.
19. Kobayashi K, Takahashi E, Miyagawa Y, Yamanaka H, Noguchi K: Induction
of the P2X7 receptor in spinal microglia in a neuropathic pain model.
Neurosci Lett 2011, 504:57–61.
20. Romero-Sandoval A, Chai N, Nutile-McMenemy N, Deleo JA: A comparison
of spinal Iba1 and GFAP expression in rodent models of acute and
chronic pain. Brain Res 2008, 1219:116–126.
21. Echeverry S, Shi XQ, Zhang J: Characterization of cell proliferation in rat
spinal cord following peripheral nerve injury and the relationship with
neuropathic pain. Pain 2008, 135:37–47.
22. Milligan ED, Watkins LR: Pathological and protective roles of glia in
chronic pain. Nat Rev Neurosci 2009, 10:23–36.
23. Inoue K, Tsuda M: Purinergic systems, neuropathic pain and the role of
microglia. Exp Neurol 2012, 234:293–301.
24. Clark AK, Malcangio M: Microglial signalling mechanisms: Cathepsin S and
Fractalkine. Exp Neurol 2012, 234:283–292.
25. Xiao HS, Huang QH, Zhang FX, Bao L, Lu YJ, Guo C, Yang L, Huang WJ, Fu
G, Xu SH, Cheng XP, Yan Q, Zhu ZD, Zhang X, Chen Z, Han ZG, Zhang X:
Identification of gene expression profile of dorsal root ganglion in the
rat peripheral axotomy model of neuropathic pain. Proc Natl Acad Sci U S
A 2002, 99:8360–8365.
26. Malin SA, Davis BM, Koerber HR, Reynolds IJ, Albers KM, Molliver DC:
Thermal nociception and TRPV1 function are attenuated in mice lacking
the nucleotide receptor P2Y2. Pain 2008, 138:484–496.
27. Tozaki-Saitoh H, Tsuda M, Miyata H, Ueda K, Kohsaka S, Inoue K: P2Y12
receptors in spinal microglia are required for neuropathic pain after
peripheral nerve injury. J Neurosci 2008, 28:4949–4956.
28. Kobayashi K, Yamanaka H, Yanamoto F, Okubo M, Noguchi K: Multiple P2Y
subtypes in spinal microglia are involved in neuropathic pain after
peripheral nerve injury. Glia 2012, 60:1529–1539.
29. Magni G, Ceruti S: P2Y purinergic receptors: new targets for analgesic
and antimigraine drugs. Biochem Pharmacol 2013, 85:466–477.
30. Caram-Salas NL, Reyes-Garcia G, Bartoszyk GD, Araiza-Saldaña CI, Ambriz-Tututi
M, Rocha-González HI, Arreola-Espino R, Cruz SL, Granados-Soto V:
Subcutaneous, intrathecal and periaqueductal grey administration of
asimadoline and ICI-204448 reduces tactile allodynia in the rat. Eur J
Pharmacol 2007, 573:75–83.
31. Mamedova LK, Joshi BV, Gao ZG, von Kugelgen I, Jacobson KA:
Diisothiocyanate derivatives as potent, insurmountable antagonists of
P2Y6 nucleotide receptors. Biochem Pharmacol 2004, 67:1763–1770.
32. Meis S, Hamacher A, Hongwiset D, Marzian C, Wiese M, Eckstein N, Royer
HD, Communi D, Boeynaems JM, Hausmann R, Schmalzing G, Kassack
MU: NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,
1-(4-methyl-phenylene)-car bonylimino))-bis(1,3-xylene-alpha, alpha'-
diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist
and stimulates release of interleukin-8 from human monocyte-derived
dendritic cells. J Pharmacol Exp Therapeut 2010, 332:238–247.
33. Okada M, Nakagawa T, Minami M, Satoh M: Analgesic effects of intrathecal
administration of P2Y nucleotide receptor agonists UTP and UDP in
normal and neuropathic pain model rats. J Pharmacol Exp Therapeut 2002,
303:66–73.
Barragán-Iglesias et al. Molecular Pain 2014, 10:29 Page 11 of 11
http://www.molecularpain.com/content/10/1/2934. Fricks IP, Maddileti S, Carter RL, Lazarowski ER, Nicholas RA, Jacobson KA,
Harden TK: UDP is a competitive antagonist at the human P2Y14
receptor. J Pharmacol Exp Therapeut 2008, 325:588–594.
35. Kobayashi K, Fukuoka T, Yamanaka H, Dai Y, Obata K, Tokunaga A, Noguchi
K: Neurons and glial cells differentially express P2Y receptor mRNAs in
the rat dorsal root ganglion and spinal cord. J Comp Neurol 2006,
498:443–454.
36. Yu J, Sheung N, Soliman EM, Spirli C, Dranoff JA: Transcriptional regulation
of IL-6 in bile duct epithelia by extracellular ATP. Am J Physiol Gastrointest
Liver Physiol 2009, 296:G563–G571.
37. Brandenburg LO, Jansen S, Wruck CJ, Lucius R, Pufe T: Antimicrobial
peptide rCRAMP induced glial cell activation through P2Y receptor
signalling pathways. Mol Immunol 2010, 47:1905–1913.
38. Ohtomo K, Shatos MA, Vrouvlianis J, Li D, Hodges RR, Dartt DA: Increase of
intracellular Ca2+ by purinergic receptors in cultured rat lacrimal gland
myoepithelial cells. Invest Ophthalmol Vis Sci 2011, 52:9503–9515.
39. Alkayed F, Kashimata M, Koyama N, Hayashi T, Tamura Y, Azuma Y: P2Y11
purinoceptor mediates the ATP-enhanced chemotactic response of rat
neutrophils. J Pharmacol Sci 2012, 120:288–295.
40. Sanada M, Yasuda H, Omatsu-Kanbe M, Sango K, Isono T, Matsuura H, Kikkawa
R: Increase in intracellular Ca2+ and calcitonin gene-related peptide release
through metabotropic P2Y receptors in rat dorsal root ganglion neurons.
Neuroscience 2002, 111:413–422.
41. Ruan HZ, Burnstock G: Localisation of P2Y1 and P2Y4 receptors in dorsal
root, nodose and trigeminal ganglia of the rat. Histochem Cell Biol 2003,
120:415–426.
42. LeBlanc BW, Zerah ML, Kadasi LM, Chai N, Saab CY: Minocycline injection
in the ventral posterolateral thalamus reverses microglial reactivity and
thermal hyperalgesia secondary to sciatic neuropathy. Neurosci Lett 2011,
498:138–142.
43. Mika J, Osikowicz M, Makuch W, Przewlocka B: Minocycline and
pentoxifylline attenuate allodynia and hyperalgesia and potentiate the
effects of morphine in rat and mouse models of neuropathic pain. Eur J
Pharmacol 2007, 560:142–149.
44. Mei XP, Xu H, Xie C, Ren J, Zhou Y, Zhang H, Xu LX: Post-injury administration
of minocycline: an effective treatment for nerve-injury induced neuropathic
pain. Neurosci Res 2011, 70:305–312.
45. Nazemi S, Manaheji H, Zaringhalam J, Sadeghi M, Haghparast A: Post-injury
repeated administrations of minocycline improve the antinociceptive
effect of morphine in chronic constriction injury model of neuropathic
pain in rat. Pharmacol Biochem Behav 2012, 102:520–525.
46. Bastos LF, Godin AM, Zhang Y, Jarussophon S, Ferreira BC, Machado RR,
Maier SF, Konishi Y, de Freitas RP, Fiebich BL, Watkins LR, Coelho MM,
Moraes MF: A minocycline derivative reduces nerve injury-induced
allodynia, LPS-induced prostaglandin E2 microglial production and
signaling via toll-like receptors 2 and 4. Neurosci Lett 2013, 543:157–162.
47. Raghavendra V, Tanga F, DeLeo JA: Inhibition of microglial activation
attenuates the development but not existing hypersensitivity in a rat
model of neuropathy. J Pharmacol Exp Therapeut 2003, 306:624–630.
48. Padi SS, Kulkarni SK: Minocycline prevents the development of
neuropathic pain, but not acute pain: possible anti-inflammatory and
antioxidant mechanisms. Eur J Pharmacol 2008, 601:79–87.
49. Zhang X, Xu Y, Wang J, Zhou Q, Pu S, Jiang W, Du D: The effect of
intrathecal administration of glial activation inhibitors on dorsal horn
BDNF overexpression and hind paw mechanical allodynia in spinal nerve
ligated rats. J Neural Transm 2012, 119:329–336.
50. Milligan ED, Twining C, Chacur M, Biedenkapp J, O’Connor K, Poole S,
Tracey K, Martin D, Maier SF, Watkins LR: Spinal glia and proinflammatory
cytokines mediate mirror-image neuropathic pain in rats. J Neurosci 2003,
23:1026–1040.
51. Zimmermann M: Ethical guidelines for investigations of experimental
pain in conscious animals. Pain 1983, 16:109–110.
52. Kim SH, Chung JM: An experimental model for peripheral neuropathy
produced by segmental spinal nerve ligation in the rat. Pain 1992,
50:355–363.
53. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL: Quantitative
assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994,
53:55–63.
54. Dixon WJ: Efficient analysis of experimental observations. Annu Rev
Pharmacol Toxicol 1980, 20:441–462.55. Yaksh TL, Rudy TA: Chronic catheterization of the spinal subarachnoid
space. Physiol Behav 1976, 17:1031–1036.
56. El-Tayeb A, Qi A, Muller CE: Synthesis and structure-activity relationships
of uracil nucleotide derivatives and analogues as agonists at human
P2Y2, P2Y4, and P2Y6 receptors. J Med Chem 2006, 49:7076–7087.
57. Koizumi S, Shigemoto-Mogami Y, Nasu-Tada K, Shinozaki Y, Ohsawa K,
Tsuda M, Joshi BV, Jacobson KA, Kohsaka S, Inoue K: UDP acting at P2Y6
receptors is a mediator of microglial phagocytosis. Nature 2007,
446:1091–1095.
doi:10.1186/1744-8069-10-29
Cite this article as: Barragán-Iglesias et al.: Role of spinal P2Y6 and P2Y11
receptors in neuropathic pain in rats: possible involvement of glial cells.
Molecular Pain 2014 10:29.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
